uniQure's Regulatory Breakthrough: A New Path for AMT-130

Regulatory Breakthrough

uniQure's second-quarter earnings call marked a pivotal inflection in the company's trajectory. The FDA's Type B meeting minutes confirmed that a BLA submission under the Accelerated approval pathway for AMT-130, based on three-year Phase I/II data, is reasonable. This represents a dramatic reversal from the agency's earlier insistence on a sham-controlled study. As CEO Matt Kapusta stated, “we reached alignment with the FDA that a BLA submission under the accelerated approval pathway for AMT-130 based on the 3-year data is reasonable.” — Matthew Kapusta, Chief Executive Officer (CEO) · 2026-07-29 Even more significant, the FDA agreed that a sham control is no longer required, instead recommending a randomized standard-of-care controlled study. Walid Abi-Saab, CMO, highlighted: “the FDA agreed that a randomized study using sham control is no longer required.” — Walid Abi-Saab, Chief Medical Officer (CMO) · 2026-07-29 The primary endpoint for this confirmatory trial will be Total Functional Capacity (TFC) at 36 months, a measure the FDA views as a more direct functional outcome than the composite cUHDRS.

This clarity is a far cry from the prior quarters, when the company faced skepticism about its natural history comparison. Earlier this year, the company was still defending its data. In a prior call, Matt Kapusta asserted, “the FDA stated that the data from the Phase 1/2 study in comparison to an external control may serve as the primary basis of a BLA submission.” — Matthew Kapusta, Chief Executive Officer · 2025-11-10 That prior assurance has now been solidified into a concrete regulatory path. The company now expects to submit the BLA in Q3 2026, and the confirmatory trial design is being finalized. As part of the plan, the FDA emphasized that the confirmatory study should be well underway at the time of accelerated approval. Management believes they can enroll the global study efficiently by prioritizing regions where AMT-130 will not yet be commercially available.

Data and Commercialization

The upcoming 4-year data readout in September will be a major catalyst. With 15 high-dose and 12 low-dose patients having 4 years of follow-up, the data will further characterize durability and safety. The company also presented encouraging early data from its epilepsy and Fabry programs. Kylie O'Keefe, Head of Commercial, underscored the commercial team's readiness: “The FDA's communication that our 3-year Phase I/II data would be acceptable as the primary basis for a BLA submission represents the regulatory clarity our commercial team has been preparing for.” — Kylie O'Keefe, Head of Patient Advocacy or similar (involved with community and treatment centers) · 2026-07-29 The company's balance sheet was strengthened via a follow-on offering, extending cash runway into 2030. Effective net cash stood at $92M as of Q1 2026, but after the offering, the company reported $810M in cash, securities, and investments, providing ample funding for launch and pipeline. This financial flexibility is critical as they invest in treatment center readiness and payer engagement. The company is engaging with Centers of Excellence and has identified over 50 sites capable of administering the intracranial procedure. The recent price action, up over 200% in the last 90 days, reflects the market's enthusiasm.

The regulatory shift also has implications for the entire gene therapy field. The confirmatory trial design with a standard-of-care comparator rather than sham represents a pragmatic compromise. The FDA's preference for the Total functional capacity endpoint over cUHDRS underscores a focus on functional outcomes. Management is also preparing for a possible AdCom, as AdCom meeting seems likely given the novelty of the therapy. Historically, the company faced an uphill battle. In a prior call, Matt Kapusta said, “All of our interactions with the FDA have been very encouraging and very supportive.” — Matthew Kapusta, Chief Executive Officer · 2025-07-29 That optimism has now been validated.

The second quarter was an important one for uniQure. We received guidance from both the FDA and MHRA, our near-term regulatory pathways for AMT-130, announced promising early data from our Fabry disease and refractory temporal lobe epilepsy programs and strengthened our balance sheet into 2030 through a follow-on offering.